Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.


Journal

Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063

Informations de publication

Date de publication:
12 2021
Historique:
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 27 11 2021
Statut: ppublish

Résumé

Although human/eukaryotic ribosomal protein L14 (RPL14/eL14) is known to be associated with a variety of cancers, its role in nasopharyngeal carcinoma (NPC) remains unclear. The aim of this study was to explore the impact of RPL14(eL14) in NPC. The results of quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemical staining revealed that the expression of RPL14(eL14) significantly reduced in NPC tissues and cells. Furthermore, the protein expression of RPL14(eL14) was linked to NPC-related clinical pathological features, including the T and N classification of Tumor Node Metastasis (TNM) staging (all p < 0.05). Cell counting kit-8 (CCK-8) assay and colony formation assay revealed that RPL14(eL14) overexpression repressed NPC cell proliferation. In cell cycle assay, RPL14(eL14) overexpression significantly blocked NPC cells in S phase. Overexpression of RPL14(eL14) repressed cell migration and invasion in NPC as shown by transwell assay and cell scratch healing assay. In addition, RPL14(eL14) was closely correlated with the expression of epithelial-mesenchymal transition (EMT) biomarkers, including E-cadherin, N-cadherin, and vimentin as detected by western blot. In conclusion, our results revealed that RPL14(eL14) may be considered as an antioncogene in NPC, which greatly suppresses cancer progression.

Identifiants

pubmed: 34057029
doi: 10.1080/21655979.2021.1932225
pmc: PMC8806664
doi:

Substances chimiques

Biomarkers, Tumor 0
Cadherins 0
Ribosomal Proteins 0
Vimentin 0
ribosomal protein L14 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2175-2186

Références

Gene. 2006 Jan 17;366(1):161-8
pubmed: 16316724
PLoS One. 2012;7(7):e41055
pubmed: 22815911
Onco Targets Ther. 2019 Dec 02;12:10535-10545
pubmed: 31849480
Biosci Rep. 2021 Jan 29;41(1):
pubmed: 33305312
Lancet Oncol. 2018 Mar;19(3):382-393
pubmed: 29428165
Medicine (Baltimore). 2020 Aug 7;99(32):e21505
pubmed: 32769887
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Toxicol Lett. 2008 Jun 10;179(1):1-5
pubmed: 18485627
PLoS One. 2014 Oct 06;9(10):e108743
pubmed: 25285958
PLoS One. 2016 Nov 3;11(11):e0166021
pubmed: 27812193
Biomed Res Int. 2020 Jun 22;2020:4234632
pubmed: 32685483
Cancer Med. 2015 Jul;4(7):1079-90
pubmed: 25924914
Front Oncol. 2019 Oct 11;9:1044
pubmed: 31681582
Bioengineered. 2021 Dec;12(1):96-107
pubmed: 33345740
J Histochem Cytochem. 2003 May;51(5):567-74
pubmed: 12704204
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4959-70
pubmed: 25197367
Biomed Res Int. 2020 Aug 7;2020:1970936
pubmed: 33134371
Clin Epigenetics. 2019 Dec 30;11(1):199
pubmed: 31888761
Front Oncol. 2018 Oct 26;8:483
pubmed: 30416986
Onco Targets Ther. 2021 Jan 19;14:551-564
pubmed: 33505161
Toxicol Lett. 2011 Mar 25;201(3):205-12
pubmed: 21195149
BMC Med Imaging. 2020 Sep 1;20(1):104
pubmed: 32873238
Semin Cancer Biol. 2012 Apr;22(2):79-86
pubmed: 22245473
Crit Rev Oncol Hematol. 1999 Jun;31(1):55-69
pubmed: 10532190
Mol Cancer Res. 2007 Feb;5(2):171-81
pubmed: 17314274
Oncotarget. 2017 Feb 14;8(7):12052-12066
pubmed: 28076843
Mol Med Rep. 2020 Sep;22(3):2478-2486
pubmed: 32705264
Int J Biol Sci. 2018 Apr 5;14(5):549-556
pubmed: 29805306
J Cancer. 2017 Oct 19;8(18):3876-3886
pubmed: 29151976
PLoS One. 2012;7(5):e37765
pubmed: 22662215
Biochem Biophys Res Commun. 2019 May 21;513(1):56-63
pubmed: 30935691
Cell J. 2016 Jul-Sep;18(2):159-64
pubmed: 27540520
J Cell Physiol. 2017 Dec;232(12):3261-3272
pubmed: 28079253
Pathol Oncol Res. 2020 Jul;26(3):1893-1901
pubmed: 31832991
Bioengineered. 2021 Dec;12(1):414-425
pubmed: 33467964
Med Oncol. 2016 Feb;33(2):11
pubmed: 26732474
Biomolecules. 2019 May 24;9(5):
pubmed: 31137733
Mol Med Rep. 2019 Mar;19(3):2065-2076
pubmed: 30664178
Biochem Pharmacol. 2012 Nov 15;84(10):1268-76
pubmed: 22842489
Mutat Res. 1998 Nov;406(1):9-23
pubmed: 9920051
J Cancer. 2020 Oct 21;11(24):7291-7301
pubmed: 33193893
Lancet Oncol. 2016 Nov;17(11):1509-1520
pubmed: 27686945
J Clin Oncol. 2015 Oct 10;33(29):3356-64
pubmed: 26351355
South Asian J Cancer. 2018 Jul-Sep;7(3):183-187
pubmed: 30112335
Nucleic Acids Res. 2020 Jul 27;48(13):7079-7098
pubmed: 32525984

Auteurs

Zunni Zhang (Z)

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

Yalong Zhang (Y)

Department of Ultrasonic Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Yuling Qiu (Y)

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

Wuning Mo (W)

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

Zheng Yang (Z)

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH